A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.
This study focuses on a type of bladder cancer that hasn't spread into the muscle, called NMIBC. The main aim is to improve how we treat this cancer. Currently, a treatment called BCG is often used, but it doesn't work for everyone. Researchers want to use new tests, called biomarkers, from tumour tissue and blood. These tests will help doctors understand how well treatments like BCG are working early on. The study will compare patients getting the usual BCG treatment with those getting a combination of Gemcitabine and BCG. By using these special tests, the hope is to identify early which patients will benefit most and which might need a different approach, ultimately leading to more effective treatments.
At a glance
What is this study about?
This research study is about a type of bladder cancer that's found early and hasn't spread deep into the bladder muscle. Doctors call this 'non-muscle invasive bladder cancer' or NMIBC. While there are good treatments, like one called BCG, it doesn't work for everyone. About half of patients find their cancer comes back or gets worse over time, even after treatment. This is why doctors are looking for better ways to figure out who will respond best and what other treatments might help.
The main idea behind this study is to use special new tests, called 'biomarkers,' to improve how we treat NMIBC. These biomarkers are like clues found in your tumour tissue and blood. They can help doctors understand how your body is responding to treatment very early on. This study will look at patients receiving the standard BCG treatment, as well as some who will receive a combination of Gemcitabine and BCG. By closely monitoring these biomarkers, researchers hope to quickly identify if the treatment is working well or if a patient might need a different approach.
The ultimate goal is to find more effective ways of fighting NMIBC. By understanding how treatments affect your body's immune system, doctors hope to develop personalised treatment plans. This could mean fewer recurrences of cancer and better long-term health for patients with NMIBC.
Key takeaways
- This study aims to find better ways to treat non-muscle invasive bladder cancer (NMIBC).
- It uses new tests (biomarkers) from blood and tissue to check how well treatments are working.
- Patients will receive either standard BCG treatment or a combination of Gemcitabine and BCG.
- The goal is to identify patients who won't benefit from standard BCG early, so they can explore other options.
- The study focuses on developing more effective immune responses against NMIBC.
- It is for patients aged 65 or over with a specific type of newly diagnosed NMIBC.
Who may be eligible?
To join this study, you must have been recently diagnosed with a specific type of non-muscle invasive bladder cancer (NMIBC) and not had the BCG treatment before. Your cancer will be classed as 'high-grade' Ta or T1, which your doctor can explain.
Also, you need to be at least 65 years old or older. Both men and women can take part.
You cannot join the study if you've had BCG treatment for bladder cancer before. Also, if you're taking medicines that weaken your immune system, like steroids, or if you've had an organ transplant, you wouldn't be able to participate.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Have I been recently diagnosed with high-risk non-muscle invasive bladder cancer (NMIBC)?
- Have I *never* had BCG treatment for bladder cancer before?
- Am I aged 65 years or older?
- Am I generally healthy and not taking medicines that suppress my immune system (e.g., for an organ transplant)?
What does participation involve?
The detailed information about what taking part involves is not fully available in this brief summary. However, if you join, you would likely undergo some extra tests that look at your tumour tissue and blood. These tests would help researchers understand how your body is reacting to the treatment. You would receive either the standard BCG treatment or a combination of Gemcitabine and BCG, following a schedule set by the study doctors. You would also have check-ups to see how the treatment is working, possibly including scans or cystoscopies (a look inside your bladder). The total length of your participation would depend on the treatment schedule and follow-up plan, but the main goal is to check responses early on.
Potential risks and benefits
Locations (1)
- Kingston Health Sciences CenterVerified postcodeKingston, Canada
Common questions
What is NMIBC?
NMIBC stands for Non-Muscle Invasive Bladder Cancer. It means the cancer is only on the surface lining of the bladder and hasn't spread into the muscle wall.
What is BCG?
BCG is a medicine often used for NMIBC. It's a type of immunotherapy that helps your own immune system fight the cancer.
What are biomarkers?
Biomarkers are like 'clues' in your body, found in blood or tissue samples. In this study, they help doctors see how your body is reacting to treatment early on.
Why combine Gemcitabine with BCG?
Researchers are studying whether combining Gemcitabine (a chemotherapy drug) with BCG might make the treatment more effective than BCG alone for some patients.
Will I know if I'm getting the new treatment or the standard one?
The study design will be explained fully by the study team. Often in these studies, it's decided randomly which treatment you receive, but you will always be informed about your care.
How to find out more
David Robert Siemens, MD
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.